JCXH-211 is under clinical development by Immorna Hangzhou Biotechnology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JCXH-211’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JCXH-211 overview
JCXH-211 is under development for the treatment of malignant solid tumor, head and neck cancer, liver cancer, melanoma, triple-negative breast cancer, esophageal cancer, high-grade glioma. The drug candidate is a lipid nanoparticle (LNP) encapsulated self-replicating mRNA encoding the human interleukin 12 (IL12) protein. It is administered by intratumor and intravenous route as injection. It is being developed based on self-replicating RNA (srRNA) technology platform. It was also under development for glioblastoma multiforme.
Immorna Hangzhou Biotechnology overview
Immorna Hangzhou Biotechnology is a biotechnology company focused on the research and development of RNA-based therapeutics and vaccines. The company is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of JCXH-211’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
